Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Aug 12, 2023
Neoadjuvant therapies are used for locally advanced non-small cell lung carcinomas, whereby pathologists histologically evaluate the effect using resected specimens. Major pathological response (MPR) has recently been used for treatment evaluation an...
BACKGROUND: Neoadjuvant immunochemotherapy has been increasingly applied to treat non-small cell lung cancer (NSCLC). However, the comparison between robotic-assisted thoracoscopic surgery (RATS) and video-assisted thoracoscopic surgery (VATS) in the...
INTRODUCTION: B downward-shifting is a rare bronchial anomaly characterized by abnormal pulmonary arteries associated with downward displacement of B and complete fusion between the right upper and middle lobes.
BACKGROUND: The detection of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer is critical for tyrosine kinase inhibitor therapy. EGFR detection requires tissue samples, which are difficult to obtain in som...
AIM: To develop a deep-learning model using contrast-enhanced chest computed tomography (CT) images to predict programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer (NSCLC).
Protein mutation detection using liquid biopsy can be simply performed periodically, making it easy to detect the occurrence of newly emerging mutations rapidly. However, it has low diagnostic accuracy since there are more normal proteins than mutate...
BACKGROUND: Only around 20-30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tu...
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
May 4, 2023
Although programmed death-(ligand) 1 (PD-(L)1) inhibitors are marked by durable efficacy in patients with non-small cell lung cancer (NSCLC), approximately 60% of the patients still suffer from recurrence and metastasis after PD-(L)1 inhibitor treatm...
RATIONALE AND OBJECTIVES: To develop an end-to-end deep learning (DL) model for non-invasively predicting non-small cell lung cancer (NSCLC) pathological subtypes based on F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (P...
Journal of magnetic resonance imaging : JMRI
Mar 25, 2023
BACKGROUND: Brain metastasis (BM) is a serious neurological complication of cancer of different origins. The value of deep learning (DL) to identify multiple types of primary origins remains unclear.
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.